Current SP appreciation, page-155

Hi Mozzarc,

Hope you are well! Just trying to get my facts right, given you are one of the SME of this stock here in HC, do I miss anything on the below?

Potential Catalysts for PAR for the rest of CY2019: (in chronological order)

1) Potential feedbacks on the treatment for the NFL players under the EA IND with the FDA (should be in late Oct or so?)
2) TGA Provisional Approval (Australia) for OA - has this been delayed to Q4? On my investment note, it was marked it could be for Q3 and we can start generating small scale revenue following submissions. Or did I mixed up the Special Access Scheme (SAS) with Provisional Approval?
3) Pre-IND meeting Phase 3 for osteoarthritis (US FDA) - Expected Q4 as confirmed by management
4) Pre-IND for Phase 2/3 for the rare disease mucopolysaccharidosis (US FDA) - Expected Q4 as confirmed by management
5) Potential TGA SAS for MPS patients in Australia

Is there anything I missed or is there any assumptions that are incorrect?

Thank you!